Logo

Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases

Share this

Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases

Shots:

  • The Veclose Extension study is a follow-on study of VeClose Study evaluating long-term outcomes at 5yrs. post-treatment with the VenaSeal Closure System in 56 patients with chronic venous disease resulted in 94.6% closure rate of the great saphenous vein (GSV)
  • The VeClose Study involves assessment of VenaSeal & ClosureFast radiofrequency ablation (RFA) device demonstrating vein closure 91.4% & 85.2% respectively for 5yrs.
  • The VenaSeal closure system is the non-tumescent- non-thermal- non-sclerosant procedure which utilizes a medical adhesive delivered endovenously to close the vein & eliminates the risk of nerve injury while treating saphenous vein

Ref: Medtronic | Image: Medtronic Endovenous

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions